Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations

H. E. Wheeler; E. R. Gamazon; A. L. Stark; P. H. O'Donnell; L. K. Gorsic; R. S. Huang; N. J. Cox; M. E. Dolan

doi:10.1038/tpj.2011.38

Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations

H. E. Wheeler, E. R. Gamazon, A. L. Stark, P. H. O'Donnell, L. K. Gorsic, R. S. Huang, N. J. Cox, M. E. Dolan

Experimental and Clinical Pharmacology

Research output: Contribution to journal › Article › peer-review

42 Scopus citations

Abstract

Platinating agents are used in the treatment of many cancers, yet they can induce toxicities and resistance that limit their utility. Using previously published and additional world population panels of diverse ancestry totaling 608 lymphoblastoid cell lines (LCLs), we performed meta-analyses of over 3 million single-nucleotide polymorphisms (SNPs) for both carboplatin-and cisplatin-induced cytotoxicity. The most significant SNP in the carboplatin meta-analysis is located in an intron of NBAS (neuroblastoma amplified sequence; P=5.1 × 10-7). The most significant SNP in the cisplatin meta-analysis is upstream of KRT16P2 (P=5.8 × 10-7). We also show that cisplatin-susceptibility SNPs are enriched for carboplatin-susceptibility SNPs. Most of the variants that associate with platinum-induced cytotoxicity are polymorphic across multiple world populations; therefore, they could be tested in follow-up studies in diverse clinical populations. Seven genes previously implicated in platinating agent response, including BCL2 (B-cell CLL/lymphoma 2), GSTM1 (glutathione S-transferase mu 1), GSTT1, ERCC2 and ERCC6, were also implicated in our meta-analyses.

Original language	English (US)
Pages (from-to)	35-43
Number of pages	9
Journal	Pharmacogenomics Journal
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/tpj.2011.38
State	Published - Feb 2013

Bibliographical note

Funding Information:
This study is supported by NIH/NIGMS Pharmacogenomics of Anticancer Agents grant U01GM61393 (NJC, MED), the University of Chicago Breast Cancer SPORE P50 CA125183 (RSH, NJC, MED), NIH/NIGMS grant K08GM089941 (RSH) and University of Chicago Cancer Center Support Grant P30 CA14599 (RSH, MED). We would like to thank the Pharmacogenomics of Anticancer Agents Cell Line Core for assistance in providing and maintaining these cell lines. In addition, we thank Marleen Welsh for phenotyping some of the ASW and CEU3 cell lines, and Wei Zhang for performing initial imputation analyses in the CHD.

Keywords

carboplatin
cisplatin
cross-population
meta-analysis
pharmacogenomics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1038/tpj.2011.38

OpenUrl availability

Full text

Cite this

@article{eb877dadd1ab4b61af8bd2fb444f0d61,

title = "Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations",

abstract = "Platinating agents are used in the treatment of many cancers, yet they can induce toxicities and resistance that limit their utility. Using previously published and additional world population panels of diverse ancestry totaling 608 lymphoblastoid cell lines (LCLs), we performed meta-analyses of over 3 million single-nucleotide polymorphisms (SNPs) for both carboplatin-and cisplatin-induced cytotoxicity. The most significant SNP in the carboplatin meta-analysis is located in an intron of NBAS (neuroblastoma amplified sequence; P=5.1 × 10-7). The most significant SNP in the cisplatin meta-analysis is upstream of KRT16P2 (P=5.8 × 10-7). We also show that cisplatin-susceptibility SNPs are enriched for carboplatin-susceptibility SNPs. Most of the variants that associate with platinum-induced cytotoxicity are polymorphic across multiple world populations; therefore, they could be tested in follow-up studies in diverse clinical populations. Seven genes previously implicated in platinating agent response, including BCL2 (B-cell CLL/lymphoma 2), GSTM1 (glutathione S-transferase mu 1), GSTT1, ERCC2 and ERCC6, were also implicated in our meta-analyses.",

keywords = "carboplatin, cisplatin, cross-population, meta-analysis, pharmacogenomics",

author = "Wheeler, {H. E.} and Gamazon, {E. R.} and Stark, {A. L.} and O'Donnell, {P. H.} and Gorsic, {L. K.} and Huang, {R. S.} and Cox, {N. J.} and Dolan, {M. E.}",

note = "Funding Information: This study is supported by NIH/NIGMS Pharmacogenomics of Anticancer Agents grant U01GM61393 (NJC, MED), the University of Chicago Breast Cancer SPORE P50 CA125183 (RSH, NJC, MED), NIH/NIGMS grant K08GM089941 (RSH) and University of Chicago Cancer Center Support Grant P30 CA14599 (RSH, MED). We would like to thank the Pharmacogenomics of Anticancer Agents Cell Line Core for assistance in providing and maintaining these cell lines. In addition, we thank Marleen Welsh for phenotyping some of the ASW and CEU3 cell lines, and Wei Zhang for performing initial imputation analyses in the CHD.",

year = "2013",

month = feb,

doi = "10.1038/tpj.2011.38",

language = "English (US)",

volume = "13",

pages = "35--43",

journal = "Pharmacogenomics Journal",

issn = "1470-269X",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations

AU - Wheeler, H. E.

AU - Gamazon, E. R.

AU - Stark, A. L.

AU - O'Donnell, P. H.

AU - Gorsic, L. K.

AU - Huang, R. S.

AU - Cox, N. J.

AU - Dolan, M. E.

N1 - Funding Information: This study is supported by NIH/NIGMS Pharmacogenomics of Anticancer Agents grant U01GM61393 (NJC, MED), the University of Chicago Breast Cancer SPORE P50 CA125183 (RSH, NJC, MED), NIH/NIGMS grant K08GM089941 (RSH) and University of Chicago Cancer Center Support Grant P30 CA14599 (RSH, MED). We would like to thank the Pharmacogenomics of Anticancer Agents Cell Line Core for assistance in providing and maintaining these cell lines. In addition, we thank Marleen Welsh for phenotyping some of the ASW and CEU3 cell lines, and Wei Zhang for performing initial imputation analyses in the CHD.

PY - 2013/2

Y1 - 2013/2

N2 - Platinating agents are used in the treatment of many cancers, yet they can induce toxicities and resistance that limit their utility. Using previously published and additional world population panels of diverse ancestry totaling 608 lymphoblastoid cell lines (LCLs), we performed meta-analyses of over 3 million single-nucleotide polymorphisms (SNPs) for both carboplatin-and cisplatin-induced cytotoxicity. The most significant SNP in the carboplatin meta-analysis is located in an intron of NBAS (neuroblastoma amplified sequence; P=5.1 × 10-7). The most significant SNP in the cisplatin meta-analysis is upstream of KRT16P2 (P=5.8 × 10-7). We also show that cisplatin-susceptibility SNPs are enriched for carboplatin-susceptibility SNPs. Most of the variants that associate with platinum-induced cytotoxicity are polymorphic across multiple world populations; therefore, they could be tested in follow-up studies in diverse clinical populations. Seven genes previously implicated in platinating agent response, including BCL2 (B-cell CLL/lymphoma 2), GSTM1 (glutathione S-transferase mu 1), GSTT1, ERCC2 and ERCC6, were also implicated in our meta-analyses.

AB - Platinating agents are used in the treatment of many cancers, yet they can induce toxicities and resistance that limit their utility. Using previously published and additional world population panels of diverse ancestry totaling 608 lymphoblastoid cell lines (LCLs), we performed meta-analyses of over 3 million single-nucleotide polymorphisms (SNPs) for both carboplatin-and cisplatin-induced cytotoxicity. The most significant SNP in the carboplatin meta-analysis is located in an intron of NBAS (neuroblastoma amplified sequence; P=5.1 × 10-7). The most significant SNP in the cisplatin meta-analysis is upstream of KRT16P2 (P=5.8 × 10-7). We also show that cisplatin-susceptibility SNPs are enriched for carboplatin-susceptibility SNPs. Most of the variants that associate with platinum-induced cytotoxicity are polymorphic across multiple world populations; therefore, they could be tested in follow-up studies in diverse clinical populations. Seven genes previously implicated in platinating agent response, including BCL2 (B-cell CLL/lymphoma 2), GSTM1 (glutathione S-transferase mu 1), GSTT1, ERCC2 and ERCC6, were also implicated in our meta-analyses.

KW - carboplatin

KW - cisplatin

KW - cross-population

KW - meta-analysis

KW - pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=84872934592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872934592&partnerID=8YFLogxK

U2 - 10.1038/tpj.2011.38

DO - 10.1038/tpj.2011.38

M3 - Article

C2 - 21844884

AN - SCOPUS:84872934592

SN - 1470-269X

VL - 13

SP - 35

EP - 43

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

IS - 1

ER -

Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this